Agenus, Inc. (AGEN)
8.36
+0.03
(+0.36%)
USD |
NASDAQ |
Oct 02, 16:00
8.345
-0.02
(-0.18%)
After-Hours: 20:00
Agenus Enterprise Value : 620.93M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 620.93M |
| October 01, 2026 | 619.65M |
| September 30, 2026 | 687.83M |
| September 29, 2026 | 686.13M |
| September 28, 2026 | 666.53M |
| September 25, 2026 | 628.60M |
| September 24, 2026 | 626.89M |
| September 23, 2026 | 622.63M |
| September 22, 2026 | 635.42M |
| September 21, 2026 | 619.65M |
| September 18, 2026 | 599.19M |
| September 17, 2026 | 572.34M |
| September 16, 2026 | 571.92M |
| September 15, 2026 | 569.79M |
| September 14, 2026 | 568.51M |
| September 11, 2026 | 560.41M |
| September 10, 2026 | 558.28M |
| September 09, 2026 | 557.00M |
| September 08, 2026 | 581.29M |
| September 04, 2026 | 615.81M |
| September 03, 2026 | 615.81M |
| September 02, 2026 | 609.42M |
| September 01, 2026 | 605.16M |
| August 31, 2026 | 588.96M |
| August 28, 2026 | 591.10M |
| Date | Value |
|---|---|
| August 27, 2026 | 597.49M |
| August 26, 2026 | 616.24M |
| August 25, 2026 | 620.93M |
| August 24, 2026 | 591.52M |
| August 21, 2026 | 609.42M |
| August 20, 2026 | 583.85M |
| August 19, 2026 | 616.66M |
| August 18, 2026 | 585.56M |
| August 17, 2026 | 569.36M |
| August 14, 2026 | 576.61M |
| August 13, 2026 | 562.97M |
| August 12, 2026 | 558.71M |
| August 11, 2026 | 555.72M |
| August 10, 2026 | 562.97M |
| August 07, 2026 | 561.26M |
| August 06, 2026 | 583.85M |
| August 05, 2026 | 596.21M |
| August 04, 2026 | 618.37M |
| August 03, 2026 | 597.91M |
| July 31, 2026 | 584.28M |
| July 30, 2026 | 601.75M |
| July 29, 2026 | 547.20M |
| July 28, 2026 | 545.92M |
| July 27, 2026 | 525.89M |
| July 24, 2026 | 519.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novavax, Inc. | 1.302B |
| Amgen, Inc. | 261.20B |
| BioCryst Pharmaceuticals, Inc. | 2.569B |
| Imunon, Inc. | 6.953M |
| Curis, Inc. | -3.007M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.567M |
| Revenue (Quarterly) | 34.52M |
| Total Expenses (Quarterly) | 35.07M |
| EPS Diluted (Quarterly) | -0.0146 |
| Gross Profit Margin (Quarterly) | 98.50% |
| Profit Margin (Quarterly) | -1.64% |
| Earnings Yield | 31.71% |
| Operating Earnings Yield | 11.62% |
| Normalized Earnings Yield | 11.94 |